The burgeoning landscape of therapy for excess body fat and type 2 diabetes is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 receptor agonists, significant variations in their pharmacological profiles and clinical investigation results are emerging. Retatruti… Read More

Showing promise in the arena of obesity treatment, retatrutide represents a different method. Unlike many existing medications, retatrutide functions as a dual agonist, at once targeting both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic polypeptide (GIP) sensors. This concurrent activation fosters several advantageous effects, like en… Read More